Four Pharmaceutical Companies Release Q3 2023 Earnings Forecasts: Biologics Sector Remains in the Red

　　【Pharmaceutical Network Industry DynamicsAccording to the statistics from the East Money Network Data Center, as of August 25, 2023, pharmaceutical companies such as CanSino Biologics, Northland, Minsheng Health, and Enhua Pharmaceutical have released their Q3 2023 earnings forecasts.
 

　　CanSino Biologics: Net Profit in the First Three Quarters to Continue Incurring Losses
 

Concord Biotech Announces on August 24, 2023, that the net profit attributable to shareholders of the listed company for the first three quarters of 2023 is still expected to incur continuous losses, amounting to -RMB 210.62 million, with a quarter-on-quarter change in performance of 3.75%.
 

Regarding the reasons for the change in performance, CanSino Biologics stated that as of the end of this reporting period, all of the company's vaccine products are still in the research and development stage, with no vaccine products yet available for market sales. The company’s main business revenue comes from technical services and the sale of research reagents for testing, which has not been sufficient to cover the company’s R&D and daily operational needs. The company has not yet turned a profit and has accumulated uncompensated losses. The commercialization of the company’s projects under development will still take time, and it is expected that the company will continue to incur losses from January to September 2023.
 

Data shows that CanSino Biologics is committed to the research and industrialization of innovative vaccines, with a rich portfolio of HPV vaccine products. The company’s R&D pipeline includes recombinant trivalent HPV vaccine, nine-valent HPV vaccine for female indications, nine-valent HPV vaccine for male indications, fifteen-valent HPV vaccine, bivalent COVID-19 vaccine, multivalent norovirus vaccine, respiratory syncytial virus vaccine, shingles vaccine, hand-foot-mouth disease vaccine, and polio vaccine, among others.
 

　　Northland: Net Profit in the First Three Quarters Will Continue to Incur Losses
 

Northland announced on August 18 that the net profit attributable to shareholders of the listed company for the period from January to September 2023 is still expected to continue incurring losses. The predicted net profit is -54.52 million yuan, with a month-on-month change of -3.45%.
 

During the reporting period, the company's main R&D products are still in the drug research and development stage. The company's revenue mainly comes from the sales revenue of its subsidiary Huienland Eye Drops, as well as the processing fee income obtained from providing entrusted processing services. The subsidiary Huienland has started to make a profit, but the parent company is still in the new drug research and development stage. The core products under research, such as NL003, still need time to be commercialized. Therefore, the company's overall net profit is still in a loss.
 

Northland mainly develops therapeutic biological products. The company has established four key technology platforms: gene vector, animal cell culture, prokaryotic cell culture, and biomacromolecule purification, providing a guarantee for the continuous development of projects. The company's new drug R&D pipeline is rich and has a relatively high level of maturity.
 

　　Minsheng Health: Net Profit in the First Three Quarters Increased by 10.21% Year-on-Year
 

Minsheng Health announced on August 11 that the company expects a net profit of 82.4817 million yuan for the first three quarters of 2023, representing a year-on-year increase of 10.21%. The growth in performance is mainly due to the expansion of the business scale.
 

It is reported that Minsheng Health focuses on the field of vitamin and mineral supplements, and is an enterprise integrating the research and development, production, and sales of over-the-counter drugs and health foods in vitamins and minerals. The company's products for sale are mainly vitamin and mineral supplement series.
 

　　Enhua Pharmaceutical: Net Profit Increased by 10% to 30% Year-on-Year
 

Enhua Pharmaceutical announced on July 31 that the net profit attributable to shareholders of the listed company for January-September 2023 is expected to be between 816 million yuan and 964 million yuan, representing a year-on-year increase of 10% to 30%. This growth is mainly due to the increase in the company's main business revenue.
 

Data shows that Enhua Pharmaceutical mainly produces and operates central nervous system drugs. Through years of relentless efforts in product development, production, and service, the company has established a complete series of central nervous system drug products and a marketing network, striving to become an important producer and seller of central nervous system drugs in China.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.